Cannabis for chronic pain: a 2026 read on the clinical evidence

The clinical literature on cannabis for pain is more nuanced than either the advocacy or the prohibition framing typically acknowledges. The honest read in 2026 is: there is real, replicated evidence for analgesic effect in specific pain syndromes, the effect sizes are modest, and the methodology of most studies is weaker than what we'd accept in other therapeutic areas.

Where the evidence is strongest

Neuropathic pain — particularly diabetic neuropathy and HIV-associated neuropathy — has the cleanest evidence base. Multiple randomized controlled trials over the last decade have demonstrated a statistically significant analgesic effect for cannabinoid formulations, with effect sizes broadly comparable to gabapentinoids but with different side-effect profiles.

Where it's weaker

Chronic non-cancer pain as a generalized category is heterogeneous, the trials are small, and the durations are short. The systematic reviews — including the National Academies report and several subsequent Cochrane reviews — consistently land on "limited-to-moderate" quality evidence and modest effect sizes. The number-needed-to-treat figures often quoted in advocacy contexts are higher than the trial data supports.

Drug interactions that aren't talked about enough

This is the clinical gap I think about most. CBD in particular is a meaningful inhibitor of cytochrome P450 enzymes, especially CYP3A4 and CYP2C9. The implications for patients on warfarin, certain anticonvulsants, immunosuppressants, and several oncology agents are real and underappreciated. Any clinician initiating cannabis therapy should review the patient's medication list with these interactions in mind.

The methodological honest answer

The reason cannabis research has the data quality it does is structural — federal scheduling has made high-powered, long-duration clinical trials extraordinarily difficult to fund and execute in the United States. That improves as research access opens up. Until it does, the evidence base will continue to be characterized by small-to-moderate trials with significant heterogeneity, and clinical recommendations should be calibrated to that reality.